title: Early immunisation with dendritic cells after allogeneic bone marrow transplantation elicits graft vs tumour reactivity.
abstract: BACKGROUND
  Perspectives of immunotherapy to cancer mediated by bone marrow transplantation (BMT) in conjunction with dendritic cell (DC)-mediated immune sensitisation have yielded modest success so far. In this study, we assessed the impact of DC on graft vs tumour (GvT) reactions triggered by allogeneic BMT.
  
  
  METHODS
  H2K(a) mice implanted with congenic subcutaneous Neuro-2a neuroblastoma (NB, H2K(a)) tumours were irradiated and grafted with allogeneic H2K(b) bone marrow cells (BMC) followed by immunisation with tumour-inexperienced or tumour-pulsed DC.
  
  
  RESULTS
  Immunisation with tumour-pulsed donor DC after allogeneic BMT suppressed tumour growth through induction of T cell-mediated NB cell lysis. Early post-transplant administration of DC was more effective than delayed immunisation, with similar efficacy of DC inoculated into the tumour and intravenously. In addition, tumour inexperienced DC were equally effective as tumour-pulsed DC in suppression of tumour growth. Immunisation of DC did not impact quantitative immune reconstitution, however, it enhanced T-cell maturation as evident from interferon-γ (IFN-γ) secretion, proliferation in response to mitogenic stimulation and tumour cell lysis in vitro. Dendritic cells potentiate GvT reactivity both through activation of T cells and specific sensitisation against tumour antigens. We found that during pulsing with tumour lysate DC also elaborate a factor that selectively inhibits lymphocyte proliferation, which is however abolished by humoral and DC-mediated lymphocyte activation.
  
  
  CONCLUSIONS
  These data reveal complex involvement of antigen-presenting cells in GvT reactions, suggesting that the limited success in clinical application is not a result of limited efficacy but suboptimal implementation. Although DC can amplify soluble signals from NB lysates that inhibit lymphocyte proliferation, early administration of DC is a dominant factor in suppression of tumour growth.
authors.affiliation: Zaizov Cancer Immunotherapy Laboratory, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
authors.forename: V
authors.initials: V
authors.lastname: Gigi
authors.forename: J
authors.initials: J
authors.lastname: Stein
authors.forename: N
authors.initials: N
authors.lastname: Askenasy
authors.forename: I
authors.initials: I
authors.lastname: Yaniv
authors.forename: S
authors.initials: S
authors.lastname: Ash
mesh_terms: D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000276:immunology*; D003713:Dendritic Cells / Q000637:transplantation*; D020350:Graft vs Tumor Effect / Q000276:immunology*; D007116:Immunization, Passive; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D009447:Neuroblastoma / Q000276:immunology / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014184:Transplantation, Homologous